6 results
To compare the efficacy of 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOC leading to healthcare visit, in addition to standard of careTo compare the efficacy of 5.0 mg/kg of crizanlizumab versus placebo on the annualized…
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months
The primary objective of this trial is to test if these favorable results with the DLBP can be upheld in a multicenter randomized controlled trial with patients up to 65 years with a displaced FNF. We hypothesize that the DLBP is superior compared…
To study the safety and efficacy of prolonged (>2 hours) end-ischemic DHOPE, by assessing the occurrence of (serious) adverse events during machine perfusion and within 30 days after liver transplantation.
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)